

63. A pharmaceutical composition comprising the isolated polypeptide of claim 35 in a pharmaceutically acceptable carrier.

D₁ 64. A pharmaceutical composition comprising the isolated polypeptide of claim 36 in a pharmaceutically acceptable carrier.

65. A pharmaceutical composition comprising the isolated polypeptide of claim 37 in a pharmaceutically acceptable carrier.--

Remarks

No new matter has been added. Support for the amendments to the claims can be found throughout the specification. For example, support for claims 26 and 27 can be found at least at page 18. Support for claim 28 can be found at least at Figures 1 and 2 and page 6, lines 4-8. Support for claim 29 can be found at page 6, lines 4-10. Support for claim 30 can be found at page 12, lines 13-14. Support for claims 31 and 32 can be found at Figure 1; at page 12, lines 13-14; and at page 6, lines 21-34, which states that all eight cysteines and the signature motif for the PDGF/VEGF family is conserved in VEGF3 and calls attention to Figure 2. From looking at Figure 2, one of ordinary skill in the art would appreciate that amino acids 69 to 82 of SEQ ID NO:2 contain the signature motif, and that the portion of VEGF3 that contains the conserved cysteines and motif includes amino acids 46 to 123 of SEQ ID NO:2. Support for claim 33 can be found, *inter alia*, in Example 3. If the procedures outlined in Example 3 are followed, a polypeptide consisting of amino acids 30 to 221 of SEQ ID NO:2 would be produced.

Support for claims 34 and 35 can be found at page 12, lines 13-14 and page 29, line 27 to page 30, line 5. Support for claims 36 and 37 can be found at page 10, lines 28-33 and page 12, lines 13-14. Support for claims 38-49 can be found at page 8, lines 16-26. Support for claims

50-56 can be found at page 18, lines 22-31. Support for claims 57-65 can be found at page 24, lines 4-12. Following entry of this amendment, claims 26-65 are pending in this application.

Summary

It is respectfully believed that this application is now in condition for examination. Early notice to this effect is respectfully requested.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Andrea Jo Kamage

Andrea Jo Kamage
Agent for Applicants
Registration No. 43,703

Date: April 8, 1999

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600